Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$0.26 USD
-0.02 (-5.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $0.26 0.00 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.26 USD
-0.02 (-5.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $0.26 0.00 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 14.71% and 40.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 66.67% and 42.27%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 12.50% and 1.52%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of -34.62% and 33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Lyra Therapeutics (LYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 101.8% upside potential for Lyra Therapeutics (LYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adherex Technologies (FENC) delivered earnings and revenue surprises of -600% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 10% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
by Zacks Equity Research
United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy From a Rebounding Industry
by Kinjel Shah
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Lyra Therapeutics, Inc. (LYRA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
by Kinjel Shah
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
Brookdale's (BKD) November 2023 Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale (BKD) witnesses 25 straight months of year-over-year increase in weighted average occupancy level.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical
by Zacks Equity Research
Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up
by Zacks Equity Research
Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery.
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 25% and 11.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -5.93% and 15.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -22.22% and 28.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.